$2.70
-0.14 (-4.93%)
Open$2.72
Previous Close$2.84
Day High$2.78
Day Low$2.66
52W High$464.00
52W Low—
Volume—
Avg Volume60.5K
Market Cap2.05M
P/E Ratio—
EPS$-10.03
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+513.0% upside
Current
$2.70
$2.70
Target
$16.55
$16.55
$10.07
$16.55 avg
$19.24
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 66.46M | 953.7K | 857.2K |
| Net Income | -10,938,014 | 90.7K | 81.5K |
| Profit Margin | -16.5% | 9.5% | 9.5% |
| EBITDA | -10,790,919 | 169.7K | 158.3K |
| Free Cash Flow | — | 104.6K | 58.4K |
| Rev Growth | +102.9% | +23.3% | +22.6% |
| Debt/Equity | — | 0.69 | 0.48 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $295.03 | +0.20% | 50.3 | 520.47B |
| AMGN | Amgen Inc | $465.67 | -0.30% | 26.9 | 252.64B |
| GILD | Gilead Sciences Inc | $168.08 | +0.08% | — | 208.95B |
| VRTX | Vertex Pharmaceuticals Inc | $538.60 | -0.74% | 33.9 | 134.82B |
| REGN | Regeneron Pharmaceuticals | $955.47 | +0.45% | 20.4 | 98.38B |
| ALNY | Alnylam Pharmaceuticals Inc | $165.04 | +5.36% | 7.7 | 20.98B |